"Underwriting" beginning on page 139 for additional information regarding underwriting compensation.Certain of our directors and existing stockholders, or their affiliates, have indicated an interest in purchasing up to an aggregate of approximately 600,000 shares of our common stock
with Alzheimer's disease, and an approved controlled-release product, Namenda XR®, which Forest developed and is marketing in the United States under a license from us.
commercialize our wholly owned product candidates, if approved, by developing a specialty CNS sales force to reach high volume prescribing neurologists and psychiatrists in the United States.Our market opportunityWe estimate that approximately 36 million people in the United States suffer from chronic CNS disorders such as Alzheimer's
are implementing our strategy by focusing on the following key objectives:•Obtain FDA approval of ADS-5102 for LID;•Develop ADS-5102 for the treatment of additional CNS indications;•Commercialize ADS-5102 by developing a specialty sales force;•Develop additional novel therapeutics based on existing CNS drugs; and•Support Forest in the NDA review and anticipated commercialization of MDX-8704.Our therapeutics portfolioOur initial product and product candidates are based on pharmacokinetic enhancements of two approved CNS drugs, amantadine and
ADS-5102, as well as Forest's successful commercialization of Namenda XR and, if approved, MDX-8704;•Our product candidates and Namenda XR require a complex manufacturing process, and there are risks associated with
a failure to meet required manufacturing specifications; Namenda XR is one of the components of Forest's fixed-dose combination product candidate MDX-8704;•We do not directly market any products, expect to incur substantial and increasing losses for the foreseeable future and
current and future products in our therapeutic portfolio, such as the possible result of the ten challenges from generic manufacturers relating to Abbreviated New Drug Applications seeking approval
immediately prior to the closing of this offering;•no exercise of the underwriters' over-allotment option to purchase additional shares of our common stock; and•a 2-for-1 forward split of our outstanding common stock and preferred stock effected on March 24, 2014.7Table of ContentsSummary Consolidated Financial DataThe following tables summarize our consolidated financial data and should be read together with the sections in this prospectus
Notes 2 and 14 to our consolidated financial statements for a description of the method used to compute basic and diluted net income per share.8Table of ContentsDecember 31, 2013ActualProForma(1)Pro FormaAsAdjusted(2)(3)(in thousands)(unaudited)Balance sheet data:Cash and cash equivalents$85,612$85,612$129,942Working capital81,79081,790126,120Total assets86,21686,216130,546Warrant liability6,232——Convertible preferred stock19,149——Total stockholders' equity$56,605$81,986$126,316(1)The
assumed initial public offering price of $17.00 per share remains the same, and after deducting estimated underwriting discounts and commissions and offering expenses payable by us.9Table of ContentsRISK FACTORSInvesting in our common stock involves a high degree of risk.
or all of your investment.Risks related to our financial condition and need for additional capitalAlthough we reported net income for 2012 and 2013, we incurred significant losses in prior years and expect to incur substantial losses in the future.We are a clinical-stage specialty pharmaceutical company and do not currently directly market any products.
dyskinesia, or LID;•develop ADS-5102 for treatment of other indications in addition to LID and develop additional product candidates;•seek regulatory approvals for our product candidates that successfully complete clinical studies;•establish a specialty CNS sales force and improve our distribution and marketing capabilities to commercialize products
our agreements with manufacturers;•expenditures that we will or may incur to acquire or develop additional product candidates and technologies;•the level of demand for our products, should any of our product candidates receive approval, which may vary significantly;•future accounting pronouncements or changes in our accounting policies;•the timing and success or failure of clinical studies for our product candidates or competing product candidates, or any
could occur even when we have met any previously publicly stated revenue and/or earnings guidance we may provide.We may need additional funds and, if we cannot raise additional capital when needed, we may have to curtail or cease operations.We are seeking to advance multiple product candidates through the research and clinical development process.
future financing requirements will depend on many factors, some of which are beyond our control, including:•the rate of progress and cost of our clinical studies;•the timing of, and costs involved in, seeking and obtaining approvals from the U.S. Food and Drug Administration, or FDA,
these drugs will depend on numerous factors, including:•successfully completing clinical studies for ADS-5102;•receiving marketing approvals from the FDA and, to a lesser extent, similar regulatory authorities outside the United
States for our product candidates;•establishing commercial manufacturing arrangements with third parties;•launching commercial sales of any of the product candidates that may be approved;•the medical community and patients accepting any approved product;•the placement of any approved products on payors' formulary tiers and the reimbursement rates for the approved products;•effectively competing with other therapies;•any approved products continuing to have an acceptable safety profile following approval; and•obtaining, maintaining, enforcing and defending intellectual property rights and claims.If
that our product candidates have unanticipated serious side effects or other unexpected characteristics or that the patients are being exposed to unacceptable health risks;•regulators may not approve our proposed clinical development plans or may require costly modifications to such plans;•regulators or institutional review boards may not authorize us or our investigators to commence a clinical study or
do, which would impair our ability to commercialize our product candidates and harm our business and results of operations.14Table of ContentsEven if clinical studies demonstrate statistically significant efficacy and acceptable safety for a product, the FDA or similar regulatory authorities outside the United
FDA were to require Forest or us to conduct additional studies of MDX-8704 or ADS-5102 to obtain approval for the product candidates in their currently contemplated indications, our business and
business, financial condition and results of operations.16Table of ContentsAny product candidate that we are able to commercialize may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare
If we are forced to abandon development of our product candidates, our business, results of operations and financial condition will be harmed.Safety issues with Namenda XR, MDX-8704 or ADS-5102, or the parent drugs or other components of Namenda XR, MDX-8704 or ADS-5102, or with approved products of third parties
caused other drugs that have the same therapeutic target, such as Celebrex from Pfizer, to receive additional scrutiny from regulatory authorities.The marketing of ADS-5102 and MDX-8704, if approved, will be limited to use for the treatment of specific indications, and if we or Forest want to expand the indications for
including:•the prevalence and severity of any side effects;•efficacy, duration of response and potential advantages compared to alternative treatments;•the price we charge;•the willingness of physicians to change their current treatment practices;•convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;•the strength of marketing and distribution support; and•the availability of third-party coverage or reimbursement.For
example, the absence of approved therapeutics to treat LID may require us to educate healthcare providers and patients about LID.Delays in the enrollment of patients in any of our clinical trials could increase our development costs and delay completion of the study.We may not be able to initiate or continue clinical studies for our product candidates if we are unable to locate and enroll a
our agreement with Forest, are subject to numerous risks, which may include that:•collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;•collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or
stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may suffer or be more volatile.Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.Our operations could be subject to earthquakes, power shortages, telecommunications failures, floods, hurricanes, typhoons, fires,
If any product candidates that we may develop are approved for commercialization outside the United States, we will be subject to additional risks related to entering into international
business relationships, including:•different regulatory requirements for drug approvals in foreign countries;•reduced protection for intellectual property rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation or political instability in particular foreign economies and markets;•difficulties in assuring compliance with foreign corrupt practices laws;•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;•foreign taxes, including withholding of payroll taxes;•foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
unable to obtain non-U.S. regulatory approval to market our product candidates in other countries, we may not be able to achieve the financial results we project and our stock price could decline.Healthcare reform measures could hinder or prevent our product candidates' commercial success.In the United States, there have been and we expect there will continue to be a number of legislative and regulatory changes to the
other things, adversely affect:•our ability to set a price we believe is fair for our products;•our ability to generate revenue and achieve or maintain profitability; and•the availability of capital.35Table of ContentsIf we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients' rights are and will be applicable
process or sales and marketing terms;•variations in our financial results or those of companies that are perceived to be similar to us;•the success of our efforts to acquire or in-license additional products or product candidates;•developments concerning our collaborations, including but not limited to those with our sources of manufacturing and our
ability to obtain patent protection for our current or future products;•our ability or inability to raise additional capital and the terms on which we raise it;•the recruitment or departure of key personnel;37Table of Contents•changes in the structure of healthcare reimbursement systems;•regulatory or legal developments in the United States and other countries, especially changes in laws or regulations
fair market value of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, immediately prior to the closing of this offering; and•on a pro forma as adjusted basis to further reflect the sale by us of 3,000,000 shares of common stock in this offering at
date the registration statement of which this prospectus forms a part is declared effective (including 1,771,212 shares of common stock reserved for issuance under our 2007 Plan, as of
incentive plans or we issue additional shares of common stock or other equity or convertible debt securities in the future, there will be further dilution to investors participating in this offering.52Table of ContentsSELECTED CONSOLIDATED FINANCIAL DATAYou should read the following selected consolidated financial data together with the "Management's Discussion and Analysis of Financial
Notes 2 and 14 to our consolidated financial statements for a description of the method used to compute basic and diluted net income per share.Year EndedDecember 31,20122013(in thousands)Balance sheet data:Cash and cash equivalents$62,957$85,612Working capital25,71581,790Total assets64,30386,216Warrant liability1,7066,232Total liabilities40,18610,462Convertible preferred stock19,14919,149Total stockholders' equity4,96856,60554Table of ContentsMANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONAND RESULTS OF OPERATIONSThe following discussion and analysis should be read in conjunction with our selected consolidated financial
eligible to receive up to an additional $55 million in payments based upon the achievement of certain regulatory milestones prior to and including the first FDA approval of MDX-8704.Financial operations overviewSummaryOur revenue to date has been generated primarily from license and development revenue pursuant to our license agreement with Forest.
initial public offering, at which time all preferred stock warrants will be converted into warrants to purchase common stock and, accordingly, the liability will be reclassified to equity.Stock-based compensationStock-based compensation cost is measured at the date of grant based on the estimated fair value of the award, net of estimated
addition, Forest is required at its expense to use commercially reasonable efforts to commercialize fixed-dose memantine-donepezil product in the United States.82Table of ContentsIn connection with the execution of the license agreement, Forest made a non-refundable, upfront payment to us of $65 million.
was eligible to receive an additional option to purchase 300,000 shares of common stock following our attainment of a designated sales milestone related to certain of our commercial products which
Plan, the board of directors has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike price of stock awards, if any, the number of shares subject to
will be used to purchase shares of our common stock within 10 business days prior to such corporate transaction, and such purchase rights will terminate immediately.ESPP amendment; termination.Our board of directors has the authority to amend or terminate our ESPP, provided that except in certain
share, the midpoint of the price range set forth on the cover page of this prospectus, immediately prior to the closing of this offering;•a 2-for-1 forward split of our outstanding common stock and preferred stock effected on March 24, 2014; and•no exercise of the underwriters' over-allotment option to purchase additional shares of our common stock.Certain of our directors and existing stockholders, or their affiliates, have indicated an interest in purchasing up to an aggregate of approximately 600,000 shares of our common stock
of the company for cash or (ii) ten years from the date of issuance, and warrants to purchase an aggregate of 85,832 shares of common stock will expire on November 26, 2014.129Table of ContentsRegistration rightsWe are party to an investor rights agreement that provides that holders of our preferred stock and certain holders of common stock that
Future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options and warrants, or the
Company's intellectual property rights in the United States in connection with the development and commercialization of MDX-8704 and marketing of Forest's approved product Namenda XR for the treatment